Article Contents ::
- 1 Details About Generic Salt :: Brimonid
- 2 Main Medicine Class:: Antiglaucoma, Alpha-2 adrenergic agonist
- 3 Alphagan Solution: 0.2% Alphagan P Solution: 0.15% Class: Antiglaucoma, Alpha-2 adrenergic agonist
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Brimonid
Main Medicine Class:: Antiglaucoma, Alpha-2 adrenergic agonist
Alphagan
Solution: 0.2%
Alphagan P
Solution: 0.15%
Class: Antiglaucoma, Alpha-2 adrenergic agonist
Drugs Class ::
Action Reduces aqueous humor production and increases uveoscleral outflow.
Indications for Drugs ::
Indications Lowers IOP in open-angle glaucoma or ocular hypertension.
Drug Dose ::
Route/Dosage
Adults and children 2 yr and older: Ophthalmic Instill 1 drop into affected eye(s) tid (approximately 8 hr apart).
Contraindication ::
Contraindications Coadministration of MAO inhibitors.
Drug Precautions ::
Precautions
Pregnancy: Category B. Lactation: Undetermined. Children: Safety and efficacy not established in children under 2 yr. Renal or hepatic function impairment: Use with caution. Soft contact lenses: Wait at least 15 min after instilling brimonidine before inserting contact lenses.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CARDIOVASCULAR: Hypertension; palpitations. CNS: Headache; fatigue; drowsiness; dizziness; depression; anxiety; syncope. EENT: Dry mouth; ocular hyperemia, burning, and stinging; blurred vision; foreign body sensation; conjunctival follicles; ocular allergy; ocular pruritus; corneal staining and erosion; photophobia; eyelid erythema and edema; ocular aching and pain; ocular dryness; tearing; conjunctival edema; blepharitis; ocular irritation; conjunctival blanching; abnormal vision; lid crusting; conjunctival hemorrhage; abnormal taste; conjunctival discharge; nasal dryness. GI: GI symptoms. RESPIRATORY: Upper respiratory tract symptoms. OTHER: Asthenia; muscle pain.
Drug Mode of Action ::
Action Reduces aqueous humor production and increases uveoscleral outflow.
Drug Interactions ::
Interactions
Antihypertensives, beta blockers, cardiac glycosides: Brimonidine may reduce pulse and BP; use with caution. CNS depressants (eg, alcohol, anesthetics, barbiturates, opiates, sedative): Additive or potentiating CNS depressant effect. MAO inhibitors: Concurrent use contraindicated. Tricyclic antidepressants: May decrease the effect of brimonidine by altering the metabolism and uptake of circulating amines.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies. Note current or recent (within 14 days) use of MAO inhibitor.
- Ensure that IOPs have been measured and documented in the patient’s record.
- Monitor patient for side effects and report to health care provider if noted and significant.
Drug Storage/Management ::
Administration/Storage
- Discontinue MAO inhibitors at least 14 days before initiating therapy.
- Instill 1 drop in the affected eye(s) tid, approximately 8 hr apart.
- If using other topical ophthalmic drugs, separate each medication by at least 5 min.
- Store at controlled room temperature. Keep container tightly closed.
Drug Notes ::
Patient/Family Education
- Explain name, dose, action, and potential side effects of drug.
- Advise patient that usual dose is 1 drop in the affected eye(s) tid, approximately 8 hr apart.
- Teach patient the following proper technique for instilling eye drops: wash hands; do not allow dropper to touch eye. Tilt head back, look up; pull lower eyelid down; instill prescribed number of drops.
- Close eye for 1 to 2 min and apply gentle pressure to bridge of nose. Do not rub eye.
- Advise patients who wear contact lenses to remove lenses before instilling this medicine and to wait at least 15 min after instilling eye drop before inserting lenses.
- Advise patient that if more than 1 topical ophthalmic drug is being used, administer the drugs at least 5 min apart.
- Advise patient that drug may cause drowsiness or fatigue and to use caution while driving or performing other activities requiring mental alertness.
- Advise patient to contact eye care physician if eye or eyelid inflammation, irritation, or itching is noted.
- Remind patient that eye examinations and measurement of IOP will be necessary while using this medication and make sure to keep appointments.